Article

Fluocinolone acetonide implant gets German marketing approval

An intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide for up to 36 months (Iluvien, Alimera Sciences Inc.), has been granted marketing authorization by the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies.

Atlanta-An intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide for up to 36 months (Iluvien, Alimera Sciences Inc.) has been granted marketing authorization by the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies.

This marketing authorization follows the completion of the decentralized regulatory procedure, in which the Medicines and Healthcare Products Regulatory Agency in the United Kingdom, serving as the reference member state, delivered a positive outcome for the implant along with six concerned members states: Austria, France, Germany, Italy, Spain, and Portugal. The German authorization is the fifth national approval in the European Union, preceded by Austria, Portugal, the United Kingdom, and France.

“We are very pleased to receive German marketing authorization for [the fluocinolone acetonide implant], our fifth of seven expected approvals in the European Union,” said Dan Myers, president and chief executive officer, Alimera Sciences. “Assuming the closing of our recently announced financing, we anticipate that we will launch [the implant] in Germany during the first quarter of 2013.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.